Baker McKenzie with Cosmo Pharmaceuticals on its public exchange offer

Cosmo Pharmaceuticals and Cassiopea have entered into a transaction agreement under which Cosmo is launching a public exchange offer in Switzerland to acquire all of the publicly-held registered shares of Cassiopea. The public exchange offer is expected to close in December 2021. After successful completion of the public exchange offer, Cassiopea will be delisted from SIX Swiss Exchange.
 
Baker McKenzie advised Cosmo Pharmaceuticals on all legal and tax aspects in connection with this exchange offer.  The Baker McKenzie Switzerland team was led by Matthias Courvoisier (partner, capital markets, pictured left) and Beau Visser (associate Zurich, capital markets, pictured right) and is comprised of Susanne Liebel–Kotz (associate Zurich, taxes), Tanja Schmid (associate Zurich, banking and finance), Elena Mani (junior associate Zurich, capital markets) and Louise Steinfels (associate Geneva, litigation).